Document Detail

FDG PET/CT in monitoring response to treatment in gynecological malignancies.
MedLine Citation:
PMID:  23299090     Owner:  NLM     Status:  In-Data-Review    
PURPOSE OF REVIEW: To evaluate the role of fluorodeoxyglucose (FDG) PET/CT as cancer response testing in gynecological malignancies.
RECENT FINDINGS: The application of FDG PET/CT in patients with endometrial and ovarian cancer to evaluate treatment response was found to have no clinical benefits.Patients with cervical cancer seem to benefit from the use of PET/CT in estimation of treatment response. The influence of different treatments on FDG uptake, timing, frequency of examination, and survival advantage are evaluated and discussed.
SUMMARY: Growing evidence supports an important role for functional imaging FDG PET/CT as a monitoring tool in patients with uterine-cervix carcinoma. Further studies are needed to establish the clinical benefits of this modality in this population.
Amnon Amit; Orit Person; Zohar Keidar
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Current opinion in obstetrics & gynecology     Volume:  25     ISSN:  1473-656X     ISO Abbreviation:  Curr. Opin. Obstet. Gynecol.     Publication Date:  2013 Feb 
Date Detail:
Created Date:  2013-01-09     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  9007264     Medline TA:  Curr Opin Obstet Gynecol     Country:  England    
Other Details:
Languages:  eng     Pagination:  17-22     Citation Subset:  IM    
aDepartment of Obstetrics and Gynecology, Gynecologic Oncology Unit bOncology Institution cDepartment of Nuclear Medicine, Rambam Healthcare Campus, Haifa, Israel.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Primary human papillomavirus testing in organized cervical screening.
Next Document:  Perioperative care in gynecologic oncology.